Literature DB >> 10936681

Role of E-cadherin in peritoneal dissemination of the pancreatic cancer cell line, panc-1, through regulation of cell to cell contact.

H Furuyama1, S Arii, A Mori, M Imamura.   

Abstract

The present study was designed to clarify the molecules responsible for peritoneal dissemination of cancer cells. We established sublines with high (HP cells) and low (LP cells) passing activity through the membrane of a transwell chamber. The cell lines were established from the human pancreatic cancer cell line, Panc-1. LP cells demonstrated an octagonal shape and tight adhesion, whereas HP cells exhibited a spindle shape and grew with less cell-cell contact in vitro. It was found that HP cells demonstrated a high degree of peritoneal dissemination in nude mice following peritoneal injection of these cells compared to LP cells. We subsequently investigated the expression of certain adhesion molecules. Consequently, we found that LP cells exhibited a stronger expression of E-cadherin than HP cells. On the other hand, there was no difference in the expression of CD44H and beta1 integrin between these two sublines. Passing activity of LP cells through the membrane of the invasion chamber increased to nearly equal levels with HP cells following treatment with anti-human E-cadherin antibody. Moreover, transfection of mouse E-cadherin cDNA into HP cells reduced both passing activity through the membrane of the invasion chamber and peritoneal dissemination in nude mice to levels similar to that of LP cells. In conclusion, these results indicated that loss of E-cadherin facilitates both passing activity in an invasion chamber and peritoneal dissemination, playing a causative role in peritoneal dissemination of cancer cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10936681     DOI: 10.1016/s0304-3835(00)00488-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  7 in total

1.  Members of the Jagged/Notch gene families are expressed in injured arteries and regulate cell phenotype via alterations in cell matrix and cell-cell interaction.

Authors:  V Lindner; C Booth; I Prudovsky; D Small; T Maciag; L Liaw
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Aberrant expression of osteopontin and E-cadherin indicates radiation resistance and poor prognosis for patients with cervical carcinoma.

Authors:  Xinqiong Huang; Yujie Qian; Hainan Wu; Xiaoxue Xie; Qin Zhou; Ying Wang; Weilu Kuang; Lin Shen; Kai Li; Juan Su; Liangfang Shen; Xiang Chen
Journal:  J Histochem Cytochem       Date:  2014-11-07       Impact factor: 2.479

3.  Relationship between expression of E-cadherin-catenin complex and clinicopathologic characteristics of pancreatic cancer.

Authors:  Yu-Jun Li; Xiang-Rui Ji
Journal:  World J Gastroenterol       Date:  2003-02       Impact factor: 5.742

4.  Caveolae mediate growth factor-induced disassembly of adherens junctions to support tumor cell dissociation.

Authors:  Lidiya Orlichenko; Shaun G Weller; Hong Cao; Eugene W Krueger; Muyiwa Awoniyi; Galina Beznoussenko; Roberto Buccione; Mark A McNiven
Journal:  Mol Biol Cell       Date:  2009-07-29       Impact factor: 4.138

5.  Regulators of epithelial mesenchymal transition in pancreatic cancer.

Authors:  Shin Hamada; Kennichi Satoh; Atsushi Masamune; Tooru Shimosegawa
Journal:  Front Physiol       Date:  2012-07-10       Impact factor: 4.566

6.  Expression of vascular endothelial growth factor and E-cadherin in human ovarian cancer: association with ascites fluid accumulation and peritoneal dissemination in mouse ascites model.

Authors:  Noriyuki Akutagawa; Akira Nishikawa; Masahiro Iwasaki; Takashi Fujimoto; Mizue Teramoto; Yoshimitsu Kitajima; Toshiaki Endo; Masabumi Shibuya; Ryuichi Kudo
Journal:  Jpn J Cancer Res       Date:  2002-06

Review 7.  Molecular mediators of peritoneal metastasis in pancreatic cancer.

Authors:  Leela Rani Avula; Brendan Hagerty; Christine Alewine
Journal:  Cancer Metastasis Rev       Date:  2020-08-11       Impact factor: 9.264

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.